Ann: Preliminary Final Report, page-2

So they did approx $39k healthcare sales in Q4, which is not great but difficult to see a run rate trend when it's the first quarter to have all the products for sale without initial stocking orders & SD or Chinese NY.
If they don't do $200k+ in H1 with SD they're in trouble IMO.

Seed sales grew a pitiful 2.4% yoy, slow progress indeed!

Personally think they'd been better off partnering up with BWX to sell,produce & promote the healthcare products. Just working on a royalty basis. Hard to see how they're going to get enough traction before the cash runs out. Only bright side is that they'll have very low product purchasing costs in the current year.